Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 204 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Venous Line Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Parental Feelings About Their Child Needing a Central Line

NCT05842356
View directory record Official record
Conditions
Critical Illness, Children, Only, Stress
Interventions
Communication Technique 2
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 22, 2026, 5:23 AM EDT
Recruiting Phase 2 Interventional

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

NCT07087860
View directory record Official record
Conditions
Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Renal Pelvis and Ureter Cancer AJCC v7
Interventions
Best Practice, Biospecimen Collection, Central Venous Cannula Insertion, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab, Plasmapheresis, Positron Emission Tomography, Questionnaire Administration, Antibody-Drug Conjugate Therapy
Other · Procedure · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 22, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer

NCT00537381
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Docetaxel, Prednisone, Intetumumab, Placebo
Drug · Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
Birmingham, Alabama • Los Angeles, California • San Bernardino, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 22, 2026, 5:23 AM EDT
Completed No phase listed Observational

Risk Factors for Thrombosis in Children With Central Venous Lines

NCT04117217
View directory record Official record
Conditions
Pediatric Venous Thromboembolism
Interventions
Labs drawn
Diagnostic Test
Lead sponsor
University of Arizona
Other
Eligibility
6 Months to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 22, 2026, 5:23 AM EDT
Completed Not applicable Interventional

Project 4B: Lower Extremity Strength Training in ICU Patients

NCT02467023
View directory record Official record
Conditions
Sepsis
Interventions
Muscle stimulation with Niveus medical stimulator, measurement of maximal isometric twitch strength, Muscle Biopsy, Muscle Biopsy Medication: Lidocaine, Muscle Biopsy Medication: Versed, Muscle Biopsy Medication: Fentanyl, Blood and Urine Sampling, ineffective muscle stimulation
Device · Procedure · Drug + 1 more
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 22, 2026, 5:23 AM EDT
Completed Not applicable Interventional

Effect of Physiologic Insulin Administration on Cognition

NCT06424652
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Blood draws, Hyperinsulinemic Euglycemic Clamp Technique Insulin Sensitivity test, Resting Metabolic Rate (RMR)
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
65 Years to 75 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 22, 2026, 5:23 AM EDT
Active, not recruiting Not applicable Interventional

A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation

NCT07187115
View directory record Official record
Conditions
Atrial Fibrillation (AF), Persistant Atrial Fibrillation
Interventions
FARAPOINT Pulsed Field Ablation System, OptiMap System (non-ablative), FARAPULSE Pulsed Field Ablation (PFA) System and Opal HDx Mapping System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
Jonesboro, Arkansas • Santa Monica, California • Athens, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 22, 2026, 5:23 AM EDT
Withdrawn No phase listed Observational

Long Term Hemodialysis Catheters (LTHD) Post Market Clinical Follow up (PMCF)

NCT04782297
View directory record Official record
Conditions
CKD, ESRD
Interventions
Long term hemodialysis catheter
Device
Lead sponsor
Medical Components, Inc dba MedComp
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 22, 2026, 5:23 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Trial of 70% Ethanol Versus Heparin to Reduce the Rate of Central Line Infections in Children With Short Bowel Syndrome

NCT01263574
View directory record Official record
Conditions
Catheter Related Infections, Short Bowel Syndrome
Interventions
70% ethanol
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Months and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Oct 22, 2026, 5:23 AM EDT
Recruiting Phase 2 Interventional

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

NCT06239220
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
PD-L1 t-haNK, Cetuximab, NAI
Biological · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 5:23 AM EDT
Completed Not applicable Interventional Results available

Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal Failure

NCT01072682
View directory record Official record
Conditions
Acute Renal Failure
Interventions
Selective cytopheretic device (SCD)
Device
Lead sponsor
SeaStar Medical
Industry
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 22, 2026, 5:23 AM EDT
Completed Not applicable Interventional Results available

A Prospective Trial of Ultrasound Versus Landmark Guided Central Venous Access in the Pediatric Population

NCT01680666
View directory record Official record
Conditions
Need for Central Venous Access
Interventions
central line placement, Ultrasound
Procedure · Device
Lead sponsor
Stanford University
Other
Eligibility
Up to 18 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Palo Alto, California • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 22, 2026, 5:23 AM EDT
Active, not recruiting Not applicable Interventional

Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

NCT06096337
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
FARAPULSE™ Pulsed Field Ablation (PFA) System, Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 22, 2026, 5:23 AM EDT
Completed Not applicable Interventional Results available

Bevacizumab w / Temozolomide PET & Vascular MRI For GBM

NCT01987830
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
MRI-PET, TMZ-PET
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 22, 2026, 5:23 AM EDT
Completed Phase 1 Interventional

Clinical Trial of ARQ 761 in Advanced Solid Tumors

NCT01502800
View directory record Official record
Conditions
Solid Tumors
Interventions
ARQ 761, ARQ 761 Weekly Administration, Bi-Weekly Administration of ARQ 761, Two Consecutive Weeks Administration of ARQ 761 with one week of rest
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 22, 2026, 5:23 AM EDT
Completed Not applicable Interventional

ICE: Intracardiac Ultrasound Within the Left Atrium During Radiofrequency Ablation of Nonvalvular Atrial Fibrillation

NCT02028143
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Biosense Webster irrigated tip catheter, Pulmonary vein isolation, ICE catheter placed through one of two existing 8F sheaths
Device · Procedure
Lead sponsor
Gregory Jones
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Kingsport, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 22, 2026, 5:23 AM EDT
Terminated Phase 2 Interventional Results available

Clinical Trial of Vincristine vs. Prednisolone for Treatment of Complicated Hemangiomas

NCT00555464
View directory record Official record
Conditions
Hemangioma
Interventions
Vincristine, Prednisone
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 6 Months
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Oct 22, 2026, 5:23 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas

NCT02868892
View directory record Official record
Conditions
Adenocarcinoma of the Cervix, Adenosquamous Cell Carcinoma of the Cervix
Interventions
Pemetrexed
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 22, 2026, 5:23 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Platelet-rich Fibrin and Grooving for Sagittal Split Osteotomy

NCT04706182
View directory record Official record
Conditions
Inferior Alveolar Nerve Injury, Nerve Injury, Neurosensory Disorder, Mandibular Nerve Injury
Interventions
Platelet-rich fibrin (PRF), Proximal segment grooving (PSG)
Procedure
Lead sponsor
Jesse Han
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 22, 2026, 5:23 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

NCT00903006
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, MK-0646, Dasatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Oct 22, 2026, 5:23 AM EDT
Completed Phase 2 Interventional

Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00007852
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, carmustine, cytarabine, etoposide, melphalan, autologous hematopoietic stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 22, 2026, 5:23 AM EDT
Completed Not applicable Interventional Results available

Midlines and Thrombophlebitis

NCT03725293
View directory record Official record
Conditions
Catheter Infection, Catheter Thrombosis, Catheter Complications
Interventions
Angiodynamics BioFlo Midline Catheter, Teleflex Arrowg+ard Blue Advanced Midline Catheter
Device
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 22, 2026, 5:23 AM EDT
Recruiting Phase 2 Interventional

Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy

NCT06145035
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
umbilical cord-derived mesenchymal stromal cells (UC-MSCs)
Biological
Lead sponsor
Roberto Bolli
Other
Eligibility
21 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Miami, Florida • Louisville, Kentucky • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 22, 2026, 5:23 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

NCT05833217
View directory record Official record
Conditions
Long COVID, Insulin Resistance, Insulin Sensitivity
Interventions
Adipose Tissue Biopsy, Steady State Plasma Glucose (SSPG) Test
Procedure · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 22, 2026, 5:23 AM EDT